All In Biotech

Drug Trial Radar · NCT06644040

A Study of TeriQ Patch in Healthy Adult Female Participants

A Randomized, Open-Label, Active-Controlled, 3-Way, Incomplete Block, Crossover, Single Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TeriQ Patch in Healthy Adult Female Participants

Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Oct 25, 2024

Primary completion

Dec 30, 2024

Study completion Dec 30, 2024

Sponsor

Lead sponsor
QuadMedicineIndustry
Sponsor type
Industry
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be a single center, open-label, active-controlled, 3-way, incomplete block, crossover, randomized, and single escalating dose study.

Conditions

  • Osteoporosis

Interventions

  • TeriQ PatchDrug

    Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart. Route of administration- Dermal patch

  • Teribone Inj.Drug

    Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch. Route of administration: Sub-cutaneous Injection

  • Forteo Inj.Drug

    Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch. Route of administration: Sub-cutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Maximum plasma concentration (Cmax)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
  2. To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Time for maximum plasma concentration (Tmax)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
  3. To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Area under curve (AUC)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
  4. To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- half lifeTime frame: 12 timepoints on baseline up to 8 hours post first dose administration
  5. To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Clearance (CL/F)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
  6. To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Volume distribution (Vd/F)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration
  7. To evaluate the pharmacokinetic (PK) endpoints of teriparatide following a single dose administration of TeriQ Patch- Mean residence rate (MRT)Time frame: 12 timepoints on baseline up to 8 hours post first dose administration

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research Ltd.

    Joondalup, Western Australia, Australia

  • Linear Clinical Research Ltd.

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.